Remedium Bio closes the first $10 million of its Series A

Remedium Bio announced on 10 August 2026 the initial close of a planned $10 million Series A financing. Lifespan Vision Ventures led the round, with Eli Lilly and Company and HKX Capital participating, and Harry Robb of Lifespan Vision Ventures joined the board.

The company’s Prometheus platform uses adipocytes — the fat cells sitting just under the skin — as the production site for therapeutic proteins. A single minimally invasive subcutaneous injection is meant to leave a depot of cells expressing the protein for years, which would replace repeated infusions or injections of the protein itself.

The part that separates it from conventional gene therapy is that the output can be turned down or up after the fact. Most gene therapies are given once and then set: whatever expression level the patient ends up with is the level they keep. Remedium says expression can be adjusted after treatment to tune dosing for an individual patient, which is also why an accessible site under the skin matters rather than an organ.

Lead programmes are in cardiometabolic disease, with others named in endocrinology, immunology, neurology and musculoskeletal disease, and a collaboration with Lilly touching obesity and type 2 diabetes.

Everything here is preclinical. The money is for preparing first-in-human studies, and the release gives no date for them.